MX2017003916A - Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma. - Google Patents

Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma.

Info

Publication number
MX2017003916A
MX2017003916A MX2017003916A MX2017003916A MX2017003916A MX 2017003916 A MX2017003916 A MX 2017003916A MX 2017003916 A MX2017003916 A MX 2017003916A MX 2017003916 A MX2017003916 A MX 2017003916A MX 2017003916 A MX2017003916 A MX 2017003916A
Authority
MX
Mexico
Prior art keywords
phenyl
methylethyl
cyclopentyl
bis
compositions
Prior art date
Application number
MX2017003916A
Other languages
English (en)
Inventor
Matunas Robert
Chen Herman
Betancourt Aimesther
Uzarama Charles
Thibert Roch
Warren Hunt Stephen Iii
Douglas Phillips Martin
Original Assignee
Millendo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millendo Therapeutics Inc filed Critical Millendo Therapeutics Inc
Publication of MX2017003916A publication Critical patent/MX2017003916A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
    • C07C273/1818—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety from -N=C=O and XNR'R"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporciona una forma de medicamento sólida novedosa de clorhidrato de N-(2,6-bis(1-metiletil)fenil)-N'-((1-(4-(dimetilami no)fenil)ciclopentil)metil)urea (también denominado como "ATR-101") adecuado para dosificación oral y composiciones, métodos y kits relacionados con la misma. ATR-101 tiene utilidad particular en el tratamiento, por ejemplo, de actividad celular corticosuprarrenal aberrante, que incluye carcinoma corticosuprarrenal (ACC), hiperplasia suprarrenal congénita (CAH) y síndrome de Cushing.
MX2017003916A 2014-09-26 2015-09-25 Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma. MX2017003916A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055964P 2014-09-26 2014-09-26
US201462086153P 2014-12-01 2014-12-01
PCT/US2015/052338 WO2016049518A1 (en) 2014-09-26 2015-09-25 Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto

Publications (1)

Publication Number Publication Date
MX2017003916A true MX2017003916A (es) 2017-06-30

Family

ID=54291659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003916A MX2017003916A (es) 2014-09-26 2015-09-25 Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma.

Country Status (9)

Country Link
US (4) US9546135B2 (es)
EP (1) EP3197435A1 (es)
JP (1) JP2017530132A (es)
CN (1) CN107205941A (es)
AU (2) AU2015320358B2 (es)
BR (1) BR112017006287A2 (es)
CA (1) CA2962597A1 (es)
MX (1) MX2017003916A (es)
WO (1) WO2016049518A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
WO2016164476A2 (en) * 2015-04-06 2016-10-13 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
CN112441941B (zh) * 2020-12-03 2022-08-02 浙江荣耀生物科技股份有限公司 一种1-(4-氨基苯基)环戊基甲腈的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
JP2005068066A (ja) * 2003-08-25 2005-03-17 Air Water Chemical Inc ２，６−ジイソプロピルアニリンの精製方法
DK2549871T3 (en) * 2010-03-23 2018-12-10 Siga Tech Inc Polymorphic form ST-246 and processes for its preparation
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
NZ630828A (en) * 2012-03-22 2016-10-28 Univ Michigan Compounds and methods for treating aberrant adrenocartical cell disorders

Also Published As

Publication number Publication date
US20160090354A1 (en) 2016-03-31
US10059660B2 (en) 2018-08-28
EP3197435A1 (en) 2017-08-02
AU2020202784A1 (en) 2020-05-14
CN107205941A (zh) 2017-09-26
AU2015320358B2 (en) 2020-05-14
US9546135B2 (en) 2017-01-17
JP2017530132A (ja) 2017-10-12
CA2962597A1 (en) 2016-03-31
AU2015320358A1 (en) 2017-05-11
BR112017006287A2 (pt) 2017-12-12
US20170305843A1 (en) 2017-10-26
US20220162160A1 (en) 2022-05-26
WO2016049518A1 (en) 2016-03-31
US20200255372A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
PH12020550622A1 (en) Kras g12c inhibitors
MX2018013983A (es) Inhibidores g12c de kras.
CL2015000942A1 (es) Compuestos de benceno sustituido.
MX2014011188A (es) Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes.
UA109924C2 (uk) Аміди аміноінданів, які мають високу фунгіцидну активність та їх фітосанітарна композиція
MX353024B (es) Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
EP2883875A4 (en) DERIVED FROM N2, N4-BIS (4- (PIPERAZIN-1-YL) PHENYL) PIRIMIDINE-2,4-DIAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE SUBSTANCE FOR PREVENTING OR TREATING CANCER
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
JO3160B1 (ar) مشتقات الفوسفات الجديدة, طريقة تحضيرها والتركيبات الدوائية التي تحتوي عليها
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
PH12016502347A1 (en) 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
JOP20190174B1 (ar) مثبطات jak1 انتقائية
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MY173573A (en) Pyridin-4-yl derivatives
CL2015000056A1 (es) Compuestos derivados de carbamato/urea, inhibidores del receptor de histamina h3; procedimiento de preparación; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de narcolepsia.
WO2014153495A9 (en) Novel stat3 inhibitors
UY34191A (es) ?N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida y sales farmacéuticamente aceptables de lamisma?.
MX2017003916A (es) Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n&#39;-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma.
NZ630033A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride
EA201500941A1 (ru) Способы и композиции для модуляции гамма-глутамилового цикла
MX2016008729A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
TR201908937T4 (tr) P38 MAP kinazı inhibe eden indanil üre bileşikleri.